Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
8.21B
Market cap8.21B
Price-Earnings ratio
-10.21
Price-Earnings ratio-10.21
Dividend yield
Dividend yield
Average volume
1.77M
Average volume1.77M
High today
$67.90
High today$67.90
Low today
$64.00
Low today$64.00
Open price
$64.96
Open price$64.96
Volume
1.73M
Volume1.73M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $66.13, with a market capitalization of 8.21B. The stock trades at a price-to-earnings (P/E) ratio of -10.21.

On 2026-04-14, Cytokinetics(CYTK) stock traded between a low of $64.00 and a high of $67.90. Shares are currently priced at $66.13, which is +3.3% above the low and -2.6% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 1.73M, against a daily average of 1.77M.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

CYTK News

Simply Wall St 20h
Did Insider Sales and Myqorzo Optimism Just Recast Cytokinetics' Investment Narrative?

Earlier this month, Cytokinetics’ Executive Vice President of Research & Development, Fady Malik, exercised stock options and sold 4,500 shares as the company p...

Did Insider Sales and Myqorzo Optimism Just Recast Cytokinetics' Investment Narrative?
Simply Wall St 2d
A Look At Cytokinetics Valuation After Strong Multi Year Shareholder Returns

Advertisement What recent performance says about Cytokinetics Cytokinetics (CYTK) has drawn investor interest after a solid run in its share price, with the s...

A Look At Cytokinetics Valuation After Strong Multi Year Shareholder Returns
TipRanks 3d
Insiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone

Insiders have been trading these 5 stocks: ((CYTK)), ((ITUB)), ((ASX)), ((CLNN)) and ((BSM)). Here is a breakdown of their recent trades and their value. Unloc...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

More CYTK News

TipRanks 4d
Cytokinetics initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Cytokinetics (CYTK) with an Overweight rating and $95 price target The firm expects Cytokinetics’ aficamten to post positive A...

TipRanks 5d
Top Cytokinetics Executive Makes Notable Stock Move

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 8, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharpe...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.